RetinAI collaborates with Novartis to provide AI solutions for ophthalmology projects

by

Dec 10 2020
RetinAI Medical AG broadcasts a multi-year collaboration with Novartis Pharma AG underneath which RetinAI’s IT options and synthetic intelligence instruments shall be employed to assist a number of initiatives in ophthalmology and digital well being. Each firms have beforehand labored efficiently on pilot initiatives on this illness space.

Carlos Ciller, PhD, CEO RetinAI Medical AG.

The primary undertaking underneath the brand new Grasp Settlement will assist a multi-center worldwide scientific research involving sufferers with neovascular age-related macular degeneration (nAMD). The research is designed to research the affect of optical coherence tomography (OCT) picture options utilizing Synthetic Intelligence (AI) on the evaluation of illness exercise. The research shall be performed in a number of scientific facilities in quite a few European nations and Canada, involving greater than 500 sufferers.

For this research, RetinAI will present its CE-marked web-based software program platform, RetinAI Discovery®, a knowledge administration platform to effectively course of knowledge at scale throughout imaging platforms and gadgets. Discovery® is used at this time by professionals to navigate imaging knowledge, compute imaging biomarkers and monitor adjustments over time for a number of the commonest types of eye illnesses. RetinAI’s instruments additionally assist diagnostic analyses and scientific workflows in addition to affected person monitoring & adherence to remedy.

Dirk Sauer, International Growth Head of the Ophthalmology Franchise at Novartis Pharma AG, sees RetinAI as a strategic accomplice for advancing eye care by way of digital innovation: “With earlier initiatives, RetinAI’s companies have enabled us to reinforce and extra effectively construction retina scans and knowledge collected from our scientific research. Along with RetinAI, we’re engaged on end-to-end options to generate swift and complete illness insights to raised deal with sufferers and enhance affected person outcomes.”


RetinAI is happy to increase and intensify our partnership with Novartis who is among the high pharma firms in ophthalmology with deep competence, dedication and deal with digital innovation in eye care. We clearly see the worth that RetinAI can convey to Novartis. Our Discovery® platform and AI instruments are enablers to extend effectivity in analysis and scientific research and we count on they will additionally enhance drugs and coverings for sufferers. We consider utilizing RetinAI’s applied sciences to assist sufferers handled with ophthalmic drugs will present enhanced illness insights and create alternatives for extra exact therapies.”

Dr. Carlos Ciller, CEO, RetinAI

Leave a Comment